RxDoctor Payments Data

Maria Timis

Family · Plano, TXNPI 1033747563

Payments from drug & device makers

$17,712in general payments, 2019–2025

Across 410 payments — averaging $43.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • Pfizer$2K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Merck$685
  • Novartis$559
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,2607%
  • Speaking & faculty fees$4,25024%
  • Travel & lodging$1,2067%
  • Food & beverage$10,42959%
  • Education$5663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen20$5,904
Pfizer18$1,663
Johnson & Johnson27$1,075
AstraZeneca(2 entities)23$1,009
Merck33$685
Novartis30$559
Incyte Corporation18$486
GSK11$467
Gilead20$362
Sobi, Inc10$331
E.r. Squibb & Sons, L.L.C.18$304
Bayer14$303
Puma Biotechnology, Inc.6$296
Eisai Inc.12$290
Daiichi Sankyo Inc.8$283
Myriad Genetic Laboratories, Inc.2$219
Apellis Pharmaceuticals, Inc.5$196
Bristol Myers Squibb5$186
Sanofi6$161
AbbVie5$159
Genmab U.S., Inc.5$148
Jazz Pharmaceuticals Inc.5$142
Dendreon Pharmaceuticals LLC4$131
Genentech USA, Inc.2$130
EMD Serono, Inc.6$124
Stemline Therapeutics Inc.5$124
Beigene USA, Inc.4$115
Pharmaessentia USA Corporation4$109
Blueprint Medicines Corporation5$105
Lilly USA, LLC6$105
Takeda Pharmaceuticals U.S.A., Inc.5$103
Astellas Pharma US Inc4$98
CTI Biopharma Corp.4$92
AVEO Pharmaceuticals, Inc.4$84
Janssen Scientific Affairs, LLC1$83
Ipsen Biopharmaceuticals, Inc2$81
Seagen Inc.4$76
Array Biopharma Inc6$74
Mirati Therapeutics, Inc.3$69
Epizyme, Inc.3$66
Karyopharm Therapeutics Inc.3$62
Regeneron Healthcare Solutions, Inc.3$61
Rigel Pharmaceuticals, Inc.3$50
Tempus AI, Inc2$47
Geron Corporation2$46
Exelixis Inc.2$41
Boehringer Ingelheim2$36
Beone Medicines USA, Inc.2$30
Taiho Oncology, Inc.1$27
Invivyd Inc1$24
Servier Pharmaceuticals LLC1$24
G1 Therapeutics, Inc.1$24
Legend Biotech USA Inc.1$23
Recordati_rare_diseases_inc.1$21
GE HealthCare1$21
Pharmacosmos Therapeutics Inc.1$21
Adaptive Biotechnologies Corporation1$21
Iovance Biotherapeutics, Inc.1$20
Kyowa Kirin, Inc.1$17
ADC Therapeutics America, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,712 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$93,103
Medicare patients
374
Services billed
3,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole97$1,380
Megestrol Acetate15$769
Dexamethasone20$322
Gabapentin17$279
Acyclovir19$156

Paid to pharmacies, not to this prescriber.

Other family in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →